Has this already been posted and I've not seen it?
http://www.drugs.com/clinical_trial...ca-reach-milestone-pre-ind-meeting-15606.html
Biovista and CFIDS Association of America Reach Milestone with Pre-IND Meeting
CHARLOTTESVILLE, Virginia and CHARLOTTE, North Carolina, May 29, 2013
/PRNewswire/ --
Biovista and the CFIDS Association of America announced today the
successful completion of the first phase of their collaboration.
Funded as part of the CFIDS' Research Institute Without Walls,
Biovista identified candidate treatments for CFS using its
state-of-the-art COSS approach. Two candidate treatments, including a
combination therapy, were identified and are being prepared for
proof-of-concept clinical trials, with an FDA pre-IND meeting
scheduled in Q3 2013.
"We are very excited to have reached this stage within a year of
starting our collaboration. We look forward to furthering our
understanding of this complex disease and developing a treatment that
will improve CFS patients' quality of life," said Dr. Andreas
Persidis, Biovista's CEO. "Our work is an example of things to come in
terms of novel collaboration models that promise to accelerate
treatment development and, through the drug repositioning approach, do
so cost effectively," Dr Persidis added.
"There is a big gap in the pipeline that moves basic laboratory
research into safe and effective treatments. Without a bridge to bring
discoveries to the clinic, laboratory research rarely becomes more
than a paper. We are providing the means for basic researchers to move
discoveries through the translational research pipeline with our
Research Institute Without Walls," said Kim McCleary, president and
CEO of CFIDS.
"Therapies for ME/CFS are an unmet medical need. This is largely due
to the lack of translating the scientific knowledge into meaningful
impact for patients," added Dr. Suzanne D. Vernon, Scientific Director
of CFIDS. "We understand the ME/CFS knowledgebase and know how to fill
this gap. Biovista recognized the opportunity for discovery. This drug
repositioning project is an excellent example of effective use of
existing information to make a new treatment discovery."
About Biovista
Biovista finds novel uses for existing drugs and profiles their side
effects using mechanism of action analysis. Biovista develops its own
pipeline in CNS, oncology, auto-immune and rare diseases and
collaborates with biopharmaceutical companies and Patient Groups on
indication expansion, portfolio de-risking, and adverse event
prediction. (http://www.biovista.com).
About CFIDS
The CFIDS Association of America is at the leading edge of ME/CFS
research. For more information, please visit The Association's web
site at http://www.cfids.org or their research blog at
http://www.Research1st.org
Contacts
Biovista
Dr. Andreas Persidis
andreasp@biovista.com
T: +1-434-242-6514
The CFIDS Association of America
Dr. Suzanne D. Vernon
sdvernon@cfids.org
Posted: May 2013
http://www.drugs.com/clinical_trial...ca-reach-milestone-pre-ind-meeting-15606.html
Biovista and CFIDS Association of America Reach Milestone with Pre-IND Meeting
CHARLOTTESVILLE, Virginia and CHARLOTTE, North Carolina, May 29, 2013
/PRNewswire/ --
Biovista and the CFIDS Association of America announced today the
successful completion of the first phase of their collaboration.
Funded as part of the CFIDS' Research Institute Without Walls,
Biovista identified candidate treatments for CFS using its
state-of-the-art COSS approach. Two candidate treatments, including a
combination therapy, were identified and are being prepared for
proof-of-concept clinical trials, with an FDA pre-IND meeting
scheduled in Q3 2013.
"We are very excited to have reached this stage within a year of
starting our collaboration. We look forward to furthering our
understanding of this complex disease and developing a treatment that
will improve CFS patients' quality of life," said Dr. Andreas
Persidis, Biovista's CEO. "Our work is an example of things to come in
terms of novel collaboration models that promise to accelerate
treatment development and, through the drug repositioning approach, do
so cost effectively," Dr Persidis added.
"There is a big gap in the pipeline that moves basic laboratory
research into safe and effective treatments. Without a bridge to bring
discoveries to the clinic, laboratory research rarely becomes more
than a paper. We are providing the means for basic researchers to move
discoveries through the translational research pipeline with our
Research Institute Without Walls," said Kim McCleary, president and
CEO of CFIDS.
"Therapies for ME/CFS are an unmet medical need. This is largely due
to the lack of translating the scientific knowledge into meaningful
impact for patients," added Dr. Suzanne D. Vernon, Scientific Director
of CFIDS. "We understand the ME/CFS knowledgebase and know how to fill
this gap. Biovista recognized the opportunity for discovery. This drug
repositioning project is an excellent example of effective use of
existing information to make a new treatment discovery."
About Biovista
Biovista finds novel uses for existing drugs and profiles their side
effects using mechanism of action analysis. Biovista develops its own
pipeline in CNS, oncology, auto-immune and rare diseases and
collaborates with biopharmaceutical companies and Patient Groups on
indication expansion, portfolio de-risking, and adverse event
prediction. (http://www.biovista.com).
About CFIDS
The CFIDS Association of America is at the leading edge of ME/CFS
research. For more information, please visit The Association's web
site at http://www.cfids.org or their research blog at
http://www.Research1st.org
Contacts
Biovista
Dr. Andreas Persidis
andreasp@biovista.com
T: +1-434-242-6514
The CFIDS Association of America
Dr. Suzanne D. Vernon
sdvernon@cfids.org
Posted: May 2013